Evogene is a biotechnology business based in the US. Evogene shares (EVGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.73 – a decrease of 8.24% over the previous week. Evogene employs 142 staff and has a trailing 12-month revenue of around $9.4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.73 |
|---|---|
| 52-week range | $1.70 - $10.40 |
| 50-day moving average | $2.52 |
| 200-day moving average | $5.62 |
| Wall St. target price | $13.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.84 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.725 from 2024-11-19
| 1 week (2024-11-13) | -8.24% |
|---|---|
| 1 month (2024-10-21) | -33.14% |
| 3 months (2024-08-20) | -57.41% |
| 6 months (2024-05-20) | 150.00% |
| 1 year (2023-11-20) | 172.94% |
|---|---|
| 2 years (2022-11-18) | -76.02% |
| 3 years (2021-11-19) | 21.3 |
| 5 years (2019-11-20) | 14.5 |
| Revenue TTM | $9.4 million |
|---|---|
| Gross profit TTM | $766,000 |
| Return on assets TTM | -28.46% |
| Return on equity TTM | -82.37% |
| Profit margin | -210.26% |
| Book value | $0.60 |
| Market Capitalization | $9.7 million |
TTM: trailing 12 months
We're not expecting Evogene to pay a dividend over the next 12 months.
Evogene's shares were split on a 1:10 basis on 24 July 2024 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Evogene shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Evogene shares which in turn could have impacted Evogene's share price.
Over the last 12 months, Evogene's shares have ranged in value from as little as $1.7 up to $10.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evogene's is 1.084. This would suggest that Evogene's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Evogene Ltd. , together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.